# Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers

> **NCT00240500** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 109 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Engerix™-B

## Key facts

- **NCT ID:** NCT00240500
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2016-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00240500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00240500, "Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT00240500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*